Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens Clinical outcome and biomarkers of efficacy
Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens Clinical outcome and biomarkers of efficacy
复制标题
DOI：
10.4161/cbt.26343
复制
发表时间：
2013-12-01
影响因子：
3.6
通讯作者：
de Braud, Filippo
中科院分区：
文献类型：
--
作者：
Pietrantonio, Filippo;Perrone, Federica;de Braud, Filippo
背景资料：很少有数据概述帕尼单抗在晚期结直肠癌患者受益于前西妥昔单抗为基础的protocols.Patients和方法的结果：30例KRaS野生型转移性结直肠癌患者与临床受益于前西妥昔单抗为基础的方案之间2004年5月和2011年10月在9个意大利机构进行了审查。入选关键标准包括因疾病进展以外的原因而中断西妥昔单抗治疗。根据既往治疗方案（0或>= 1）、既往缓解或稳定、转移灶手术和Kohne预后评分对患者进行分类。结果：帕尼单抗的疾病控制率为67%，客观缓解率为30%，中位PFS为4.2个月，中位OS为9.6个月。BRaF/nRaS/Pi 3 KCa和KRaS（突变富集技术）野生型肿瘤患者对panitumumumab.Conclusions的反应最好的机会：单药帕尼单抗提供了显着的临床效益，在大量预处理的患者没有获得性耐药前西妥昔单抗为基础的方案。
Background: Few data are available outlining outcomes of panitumumab in advanced colorectal cancer patients benefiting from prior cetuximab-based regimens.Patients and methods: Thirty patients with KRaS wild type metastatic colorectal cancer with clinical benefit from prior cetuximab-based regimens between May 2004 and October 2011 were reviewed at nine italian institutions. inclusion key criteria included interruption of cetuximab for reasons other than progressive disease. Patients were classified according to prior regimens (0 or >= 1), prior response or stabilization, surgery of metastases, and Kohne prognostic score. at the time of subsequent progression, patients were treated with single agent panitumumab until progressive disease, unacceptable toxicity, or consent withdrawal.Results: Panitumumab obtained 67% disease control rate and 30% objective response rate, with median PFS of 4.2 and median OS of 9.6 mo. Patients with BRaF/nRaS/Pi3KCa and KRaS (by mutant enriched technique) wild-type tumors had the best chance of response to panitumumab.Conclusions: Single agent panitumumab provided significant clinical benefit in heavily pretreated patients without acquired resistance to prior cetuximab-based regimens.